bevacizumab,trifluridine tipiracil
taiho pharma,roche,pfizer
[]
nuestro granito de arena en #gi23: effect of tabernero's prognostic subgroups or development of neutropenia on survival outcomes of patients with refractory metastatic colorectal cancer (mcrc) treated with trifluridine/tipiracil plus bevacizumab (tasbev) in real-world practice. 
Oncóloga medica y doctora en medicina. Tumores digestivos y neuroendocrinos. Medical Oncologist. MD PhD. GI and endocrine tumors. Email: nmartinezlago@gmail.com